GlassScriptPhysician profile
Kieran Slevin
NPI 1588693675
$20,821.85
in general payments reported to CMS, 2019-2025
51 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 79% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,579 · 2020: $688 · 2021: $1,938 · 2022: $3,313 · 2023: $2,457 · 2024: $2,800 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,303.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $5,980.05 | 2019-2021 | |
| Abbott Laboratories | $5,728.36 | 2019-2025 | Proclaim, Octrode, Eterna |
| Boston Scientific Corporation | $2,730.14 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Nevro Corp. | $1,731.31 | 2019-2023 | Senza |
| Collegium Pharmaceutical, INC. | $462.69 | 2019-2024 | Belbuca, Xtampza |
| Forte Bio-Pharma LLC | $433.37 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $426.09 | 2019-2025 | Ztlido |
| Stryker Corporation | $321.44 | 2022-2023 | Everest Spinal System, Vitoss |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.09 | 2020-2024 | Relistor |
| Spinal Simplicity, LLC | $198.38 | 2025 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $191.99 | 2021-2023 | Nalu Neurostimulation System |
| Xtant Medical INC | $191.53 | 2025 | |
| Foundation Fusion Solutions, LLC | $174.76 | 2022-2025 | |
| Spr Therapeutics, INC | $173.16 | 2023 | Sprint Pns System |
| Zimmer Biomet Holdings, INC. | $170.13 | 2023 | Comprehensive, Gel-One Cross-Linked Hyaluronate |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kieran Slevin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.